Your AI-Trained Oncology Knowledge Connection!
S. Lindsey Davis, MD, an assistant professor of medicine and gastrointestinal medical oncologist at the University of Colorado Cancer Center, discusses an investigational immunotherapy combination being explored in patients with HER2-positive gastric and gastroesophageal junction (GEJ) cancer.
S. Lindsey Davis, MD, an assistant professor of medicine and gastrointestinal medical oncologist at the University of Colorado Cancer Center, discusses the role of ramucirumab (Cyramza) in the treatment of patients with gastric/gastroesophageal junction (GEJ) adenocarcinoma.
Christopher Lieu, MD, director, GI Medical Oncology Program and deputy associated director for clinical research, at the University of Colorado Cancer Center, discusses the rationale for combined MEK, VEGF, and PD-1 inhibition in microsatellite stable (MSS) colorectal cancer (CRC).
Christopher Lieu, MD, director, GI Medical Oncology Program and deputy associate director for clinical research, at the University of Colorado Cancer Center, discusses the predictive value of BRAF V600E mutations in metastatic colorectal cancer (mCRC).
Now, investigators are combining BRAF inhibitors with other targeted therapies in an effort to establish a new chemotherapy-free standard in patients with metastatic colorectal cancer.
Christopher Lieu, MD, director, GI Medical Oncology Program and deputy associate director for clinical research, at the University of Colorado Cancer Center, discusses investigational immunotherapy strategies in metastatic colorectal cancer (mCRC).
S. Lindsey Davis, MD, an assistant professor of medicine and gastrointestinal medical oncologist at the University of Colorado Cancer Center, discusses caveats of the phase III KEYNOTE-062 trial findings in gastric and gastroesophageal junction (GEJ) cancer.
Christopher Lieu, MD, director, GI Medical Oncology Program and deputy associated director for clinical research, at the University of Colorado Cancer Center, discusses HER2-directed therapy for patients with colorectal cancer (CRC).
S. Lindsey Davis, MD, an assistant professor of medicine and gastrointestinal medical oncologist at the University of Colorado Cancer Center, discusses the potential for maintenance therapy in gastric cancer.
Christopher Lieu, MD, highlights updates on biomarker-directed therapy with colorectal cancer and ongoing research being done with immunotherapy.
S. Lindsey Davis, MD, highlights the latest immunotherapy developments and other advances in gastric and gastroesophageal junction cancers.
Brigatinib reduced the risk of disease progression or death by more than 50% compared to crizotinib in adult patients with ALK-positive, locally advanced or metastatic NSCLC.
Paul A. Bunn Jr, MD, discusses the potential for new agents to treat small cell lung cancer, the challenges involved in treating this population, and the ongoing search for biomarkers to guide treatment decisions.
Daniel A. Pollyea, MD, MS, assistant professor of Medicine at the University of Colorado Cancer Center and clinical director of Leukemia Services at the CU School of Medicine, discusses recent advances in the treatment landscape of acute myeloid leukemia.
Ivosidenib induced an overall response rate of 41.6% (95% CI, 32.9-50.8) in patients with IDH1-positive relapsed/refractory acute myeloid leukemia.
Results of a new study found that less than half of patients with advanced cervical cancer are receiving all 3 of the therapies considered standard of care for the disease: external beam radiation therapy, brachytherapy, and chemotherapy.
The impact upon cancer care, made by Paul Bunn, MD, extends far beyond the programs he helped build in Colorado.
